2024 Neonatal & Developing Lung Abstract Achievement Awardee, Raquel Arroyo, PhD, PharmD
Congratulations to Raquel Arroyo, PhD, PharmD on winning the 2024 Neonatal & Developing Lung Abstract Achievement Award. Raquel Arroyo, PhD, PharmD is the Director of Clinical Sciences at Airway Therapeutics. She has been working with SP-D for 10+ years in academia and industry. Raquel has published several papers and presented in international scientific meetings. Her work …
Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Further plans for expansion in Europe include up to ten clinical trial sites across Spain by end of Q32022 and up to three sites in Italy by end of 2022 Zelpultide alfa has been approved as the generic name for our AT-100 (rhSP-D) by the two governing organizations, the United States Adopted Names (USAN) Council …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, GEORGIA (March 31, 2022) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
Novel therapeutic AT-100 offers potential to reduce inflammation, associated injury and incidence of secondary infection, and inhibit viral replication and promote viral elimination in severely ill, mechanically-ventilated COVID-19 patients. Initial data readout anticipated in Q4 2021 CINCINNATI, OH (August 26, 2021) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100’s Second Indication in Severe COVID-19 Patients
Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients CINCINNATI, OH (April 12, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, OH (March 26, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to …
Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus
AT-100 production expected to begin in June CINCINNATI, OH & BASEL, Switzerland (May 20, 2020) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and …
Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus
Data demonstrate AT-100 (rhSP-D) – novel human recombinant protein – reduces infection in a range of bacteria and virus-driven respiratory diseases with potential to treat COVID-19 CINCINNATI, OH (March 11, 2020) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with …
Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases
Initiating bronchopulmonary dysplasia (BPD) clinical trial in very preterm infants in 2020 with orphan drug designation Advancing preclinical research in influenza, RSV, cystic fibrosis Bolsters executive leadership with key finance and regulatory hires CINCINNATI, OH (January 8, 2020) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the injury …
Airway Therapeutics Announces Appointment of Chief Medical Officer
(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human …
